Breakthrough Immunoglobulin Therapy Yimmugo® Now Available in the U.S.
Key Takeaways
- Yimmugo® is a newly FDA-approved immunoglobulin therapy for primary immunodeficiencies.
- Kedrion Biopharma will distribute Yimmugo® in the U.S. starting in early 2025.
- The production of Yimmugo® takes place in a state-of-the-art laboratory in Germany.
Did You Know?
Kedrion Biopharma Partners With Biotest AG
Kedrion Biopharma Inc. has recently announced a significant partnership with Biotest AG to distribute the newly FDA-approved immunoglobulin therapy Yimmugo® in the U.S. The FDA granted the approval of Yimmugo® on June 13, 2024, which marks a vital development in the treatment options available for primary immunodeficiencies (PID).
With the agreement in place, Kedrion Biopharma is expected to start the commercialization and distribution of Yimmugo® by the beginning of 2025. Biotest will supply Yimmugo® starting in the fourth quarter of 2024.
What is Yimmugo®?
Yimmugo® is a polyvalent immunoglobulin G preparation derived from human blood plasma, designed for intravenous administration. It is specifically intended for patients aged two years and above who suffer from primary immunodeficiencies (PID). This group of disorders affects around 500,000 individuals in the United States.
The primary function of Yimmugo® is to enhance the immune system, thereby preventing infections and improving overall quality of life for patients with compromised immune systems.
High-Tech Production Facility
Yimmugo® is produced in Biotest’s state-of-the-art
References
- FDA Approves Yimmugo®https://www.fda.gov/news-events/press-announcements/fda-approves-yimmugo
- Primary Immunodeficiency (PID): Symptoms and Treatmenthttps://www.nih.gov/health-information/primary-immunodeficiency-symptoms-treatment
- Kedrion Biopharma Official Websitehttps://www.kedrion.com
- Biotest AG Official Websitehttps://www.biotest.com
